4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Ulcerative Colitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1862 ongoing clinical trials involving Ulcerative Colitis
Of the 1862 trials,725 trials are in Phase III
Furthermore, 532 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Ulcerative Colitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Ulcerative Colitis, a Gastrointestinal condition. The largest number of ongoing clinical trials for Ulcerative Colitis is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Ulcerative Colitis-related drug trials.

Takeda Pharmaceutical Co Ltd: The leading ongoing Ulcerative Colitis related clinical trial sponsor

Takeda Pharmaceutical Co Ltd is the top sponsor for Ulcerative Colitis-related ongoing clinical trials.

Pfizer Inc, AbbVie Inc, Johnson & Johnson and Eli Lilly and Co are among other notable clinical trial sponsors involved in Ulcerative Colitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Ulcerative Colitis

Adalimumab (Humira), Ustekinumab (Stelara) and Vedolizumab (Entyvio/ Kynteles) are among the key marketed drugs involving Ulcerative Colitis.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as injection for subcutaneous route of administration. Adalimumab was first approved in 2002 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including AbbVie Inc.

Ustekinumab (Stelara) is a human monoclonal antibody used as immunosuppressant. It functions via Interleukin 12 Subunit Beta Inhibitor: Interleukin 23 Subunit Alpha Inhibitor mechanism of action. Ustekinumab is formulated as an injectable solution for injection, powder for solution and solution for injection in pre-filled syringe and is administered by subcutaneous route and intravenous administration and injectable concentrate solution for subcutaneous route of administration. Ustekinumab was first approved in 2008 and is marketed globally in the US, UK, France, Germany, China and Japan by Janssen Biotech Inc and its subsidiaries.